Herman Waldmann: Timeline of key events

Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

The drug dramatically improves the patient's condition.1991-01-01T00:00:00+0000BTG starts negotiations to license Campath to a commercial partner.1993-01-01T00:00:00+0000Waldmann takes up a position in the William Dunn School of Pathology, 1994-01-01T00:00:00+0000The move is prompted by Waldmann's Oxford University appointment.1994-01-01T00:00:00+0000Roy Calne, Peter Friend and Waldman's team launch a small trial with 31 kidney transplant patients to see if Campath-1H can help in reducing immunosuppressant drugs. 1997-01-01T00:00:00+0000Analysis of 29 MS patients given MS indicate Campath-1H might be more effective if given earlier in the course of the disease.1998-01-01T00:00:00+0000Campath-1H shown to help lower the amount of immunosuppressant drugs taken by organ transplant patients. 2011-01-01T00:00:00+0000Granted by European regulatory authorities.2013-09-17T00:00:00+0000Alemtuzumab was originally developed by Herman Waldmann as a laboratory tool to investigate immune tolerance. It soon became the first humanised monoclonal antibody drug. Initially alemtuzumab proved effective for helping prevent graft-versus host disease in transplant patients. It subsequently went on to be approved as a treatment for leukaemia and then many years later it was shown to be effective against multiple sclerosis. 2013-09-17T00:00:00+0000
Date Event People Places Sciences
1991The first MS patient is given Campath-1HWaldmann, hale, CompstonCambridge UniversityCampath
1993The rights to Campath are assigned to the British Technology Group (BTG).WaldmannCambridge UniversityCampath
1994Waldmann moves to Oxford University.WaldmannOxford UniversityCampath
1994The TAC relocates to Oxford.Hale, WaldmannOxford UniversityCampath
1997Small scale tests launched with Campath-1H for organ transplant patients.Waldmann, Calne, FriendCambridge UniversityCampath
1998Analysis of 29 MS patients given MS indicate Campath-1H might be more effective if given earlier in the course of the disease.Compston, Coles, Waldmann, HaleCambridge UniversityCampath
2011Positive results from trials using Campath-1H for organ transplant patientsWaldmann, CalneCambridge UniversityCampath
Sep 2013Campath-1H gains marketing approval for the treatment of MS.Waldmann, Compston, ColesCambridge UniversityCampath
17 Sep 2013European Commission approved Alemtuzumab (Lemtrada) for MS treatmentCompston, Coles, WaldmannCambridge University, SanofiMonoclonal antibodies, Campath

1991

The first MS patient is given Campath-1H

1993

The rights to Campath are assigned to the British Technology Group (BTG).

1993

Waldmann moves to Oxford University.

1994

The TAC relocates to Oxford.

1997

Small scale tests launched with Campath-1H for organ transplant patients.

1998

Analysis of 29 MS patients given MS indicate Campath-1H might be more effective if given earlier in the course of the disease.

2011

Positive results from trials using Campath-1H for organ transplant patients

Sep 2013

Campath-1H gains marketing approval for the treatment of MS.

17 Sep 2013

European Commission approved Alemtuzumab (Lemtrada) for MS treatment